
    
      This is an open label study. The study will consist of 1 treatment group: coated Nifedipine
      suppository containing 12 mg of Nifedipine. Approximately 20 subjects will participate into
      this 8-week study. A screening visit will be used to determine subject suitability for
      inclusion in the trial. Within one week of the screening visit, subjects who meet all
      inclusion criteria and none of the exclusion criteria will receive Coated Nifedipine 12 mg
      Suppository X2 a day (BID) (24 mg/day total) for a period of 8 weeks. During this period, 4
      study visits (at 0, 2, 5, and 8 weeks) will take place. Study medication will be administered
      BID (in the morning and in the evening). In addition to receiving study medication, subjects
      will be maintained on a standard treatment for Anal Fissure: sitz baths, high fiber diet.
    
  